Redeye states that Acconeer's Q2 2025 report fell short of its expectations for both sales and EBITDA. A redeeming feature of an otherwise challenging quarter was a decent order intake across key verticals. Redeye believes H2 2025 will be a critical juncture for the share. Redeye posits that A111 sales must increase to continue inventory digestion, while a significant portion of the 2027 net sales target exceeding SEK300m is contingent on a successful A2 launch. From this perspective, H2 2025 will be important for news flow. Redeye has calibrated its estimates and revised its fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/